Test Information: The C3G Functional Panel includes 21 pathway, autoantibody, and biomarker tests implicated in C3 Glomerulopathy (C3G), which includes Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN).

Functional assays, enzyme-linked immunosorbent assay (ELISA), turbidimetric assays and immunofixation electrophoresis (IFE) are utilized to assess the functionality and integrity of the complement system in patients with C3 Glomerulopathy.

2014年11月7日 · C3 glomerulopathy (C3G) applies to a group of renal diseases defined by a specific renal biopsy finding: a dominant pattern of C3 fragment deposition on immunofluorescence. The primary pathogenic mechanism involves abnormal control of the alternative complement pathway, although a full description …

2024年9月12日 · The C3b deposition assay (C3bDA) quantifies complement-mediated C3b deposition on cell surfaces following activation of the alternative pathway (AP). In brief, patient serum is diluted in a buffer conducive to AP activation and applied to cultured MES-13 cells, which are then incubated at 37°C for 20 minutes.

C3 glomerulopathy (C3G) describes a pathologic pattern of injury diagnosed by renal biopsy. It is characterized by the dominant deposition of the third component of complement (C3) in the renal glomerulus as resolved by immunofluorescence ...

Advances in immunology and the emergence of novel complement-targeted therapies have shifted the focus toward identifying the distinct underlying etiologies of C3G. In this review, we provide a description of the current landscape and challenges faced in the classification, evaluation, and treatment of patients with C3G.

What is C3 Glomerulopathy (C3G) The kidney is susceptible to immune mediated injury by a variety of auto-immune insults. A rare subgroup is C3 Mediated glomerulonephritis (C3G) in which complements (particularly C3), which form the innate immune system, drive the disease process. C3G is driven by

2023年10月23日 · In adult population, we propose a three-point C3G prognostic score based on biomarkers profiles at risk, eGFR at presentation and genetic findings, which stratifies adult patients into subgroups that require close monitoring and more aggressive therapy. Keywords: C3 glomerulopathy, C3, sC5b-9, biomarker.

3 天之前 · C3G is a group of kidney diseases caused by abnormal activation of the alternative pathway of the complement system. Glomerular immunofluorescence is dominated by complement C3 deposition, that is, patients whose immunofluorescence intensity of C3c is ≥2+ compared with the fluorescence intensity of other immunoglobulins can be diagnosed as "glomerulonephritis dominated by C3 deposition", but ...

It requires ethylenediamine tetraacetic acid plasma samples and includes biochemical evaluation of the CAP, assays for autoantibodies targeting the CAP, or the common final pathway and complement gene profiling. The initial step is the measurement of C3 and C4 levels.